Value-Based Cancer Care Issues


June 2014, Vol 5, No 5

AVBCC Expert Panel: Impact of Personalized Medicine on Future and Current Therapies

Wayne Kuznar

AVBCC 2014 4th Annual Conference

Los Angeles, CA—Increasing complexities in diagnostic science, the development of precision medicine, and the use of targeted agents require un­precedented levels of collaboration between pharmaceutical manufacturers, government agencies, and payers, said oncology experts during a panel discussion on personalized medicine at the Fourth Annual Conference of the Association for Value-Based Cancer Care. [ Read More ]

The Value of Personalized Medicine Lies in Evidence Thresholds, Drug Testing, and Pricing Trends

Wayne Kuznar

AVBCC 2014 4th Annual Conference

Los Angeles, CA—Although targeted drug development and testing are clearly transforming medicine, resistance to greater uptake of personalized medicine includes a shift in the evidence threshold in personalized testing and drawbacks to the delivery system, including the cost of molecular tests, said Peter B. Bach, MD, Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center, New York, at the Fourth Annual Conference of the Association for Value-Based Cancer Care. [ Read More ]

Study Identifies Troubling Trends in NSCLC Trials

In the Literature

Changes in the design and interpretation of phase 3 trials for advanced non–small-cell lung cancer (NSCLC) have begun to emerge regarding statistical power, sample size, and the primary end points used. In a new study, researchers explored how the design and interpretation of these trials has changed over the past 3 decades. [ Read More ]

Delaying ADT for PSA-Only Relapse May Be Viable Option for Men with Prostate Cancer and PSA-Only Relapses

Wayne Kuznar

ASCO 2014 Highlights

Chicago, IL—Delaying androgen deprivation therapy (ADT) for at least 2 years did not lead to worse overall survival or prostate cancer–specific survival compared with the initiation of ADT within 3 months of rising prostate-specific antigen (PSA) in men with PSA-only relapse (ie, biochemical relapse) after the primary treatment of prostate cancer with surgery or radiation, according to the results of a large population-based study presented at the 2014 American Society of Clinical Oncology (ASCO) meeting and highlighted at a press briefing. [ Read More ]

Obesity Ups Death Risk in Premenopausal Patients with ER-Positive, but Not ER-Negative, Breast Cancer

Phoebe Starr

ASCO 2014 Highlights

Chicago, IL—Obesity increased the risk for breast cancer–associated death in premenopausal patients with estrogen receptor (ER)-positive breast cancer, had little effect in postmenopausal women with ER-positive disease, and had no effect in patients with ER-negative disease, according to results of a large study of 80,000 women with early breast cancer that were reported at the 2014 American Society of Clinical Oncology (ASCO) meeting. [ Read More ]

AZD9291, a Novel Mutation-Selective EGFR Inhibitor, May Overcome EGFR-TKI Resistance

Phoebe Starr

ASCO 2014 Highlights

Chicago, IL—AZD9291, a novel mutation-selective tyrosine kinase inhibitor (TKI), may become a treatment option for patients with advanced, EGFR-mutated non–small-cell lung cancer (NSCLC) that has progressed with standard EGFR inhibitors, according to results of a phase 1 study presented at the 2014 American Society of Clinical Oncology (ASCO) meeting and highlighted at a press briefing. [ Read More ]

Aetna’s Model of Value-Based, Financially Viable Accountable Care Improves Health Outcomes

Rosemary Frei, MSc

Economics of Cancer Care

Charles Kennedy, MD, Chief Executive Officer of Aetna’s Accountable Care Solutions, is responsible for leading Aetna’s accountable care partnerships with healthcare providers. Dr Kennedy also serves as the health insurance industry representative on the Health IT Policy Committee, a federal advisory committee that makes recommendations to the National Coordinator for Health IT on a policy framework for the development and adoption of a nationwide health information infrastructure. [ Read More ]